Teacher Retirement System of Texas Grows Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Teacher Retirement System of Texas increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 16.0% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 74,425 shares of the medical equipment provider's stock after acquiring an additional 10,267 shares during the period. Teacher Retirement System of Texas' holdings in Zimmer Biomet were worth $7,862,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ZBH. CKW Financial Group increased its holdings in Zimmer Biomet by 11.7% in the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. Romano Brothers AND Company boosted its position in Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock valued at $1,000,000 after buying an additional 102 shares during the period. Dorsey & Whitney Trust CO LLC grew its stake in shares of Zimmer Biomet by 2.3% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after acquiring an additional 102 shares in the last quarter. M&T Bank Corp boosted its holdings in Zimmer Biomet by 0.4% in the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock valued at $2,834,000 after purchasing an additional 108 shares during the period. Finally, Dakota Wealth Management grew its stake in Zimmer Biomet by 1.3% during the 4th quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider's stock worth $1,016,000 after purchasing an additional 122 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Stifel Nicolaus increased their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and issued a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays lowered their price objective on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research report on Monday, February 10th. Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Trading Down 1.3 %

Zimmer Biomet stock traded down $1.42 during midday trading on Tuesday, reaching $109.82. The stock had a trading volume of 474,643 shares, compared to its average volume of 1,496,400. The stock has a market capitalization of $21.86 billion, a PE ratio of 24.64, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The stock's 50-day simple moving average is $106.86 and its 200 day simple moving average is $106.86.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 earnings per share. Analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.